Unbuzzd Wellness names Michael Zapolin as CEO ahead of planned stock listing
Quantum BioPharma said Unbuzzd Wellness appointed Zapolin, who takes on financing and listing the company while overseeing a national U.S. commercial rollout.
SEC filing
Latest
3 stories
Thursday, September 24
Friday, August 14
Quantum BioPharma gets FDA nod to start Lucid-MS Phase 2 trial in progressive MS
The company reported Q2 2026 results alongside FDA clearance to advance its lead MS candidate into a randomized, placebo-controlled trial.
SEC filing
Monday, August 10
Quantum BioPharma gets FDA clearance to start Lucid-MS Phase 2 in progressive MS
The company said the IND for Lucid-21-302 was cleared on Aug. 10, 2026, opening the way for a randomized, double-blind, placebo-controlled trial in progressive multiple sclerosis.
SEC filing